FDA Acceptance of NDA for Tiopronin by Casper Pharma
The FDA has accepted the New Drug Application (NDA) 212927 for Tiopronin submitted by Casper Pharma, indicating a standard review process.
Therapeutic Area
Therapeutic area intelligence for Cystinuria with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.